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Considering the role of von Willebrand factor (vWf) in hemostasis, and the role of oxidative stress in the development of
endothelial dysfunction and atherosclerotic disease, the aim of our study was to investigate the relationship between vWf,
parametersofoxidativestressanddiﬀerenttypesofacutecoronarysyndromes(ACS).LevelsofvWfactivity(vWfAct),vWfantigen
(vWfAg), nitric oxide (estimated through nitrites–NO2
−), superoxide anion radical (O2
−), hydrogen peroxide (H2O2), index of
lipid peroxidation (estimated through thiobarbituric acid reactive substances–TBARS), superoxide dismutase (SOD) and catalase
(CAT) activity of 115 patients were compared with those of 40 healthy controls. ACS patients had signiﬁcantly higher vWfAct and
vWfAg levels, as well as TBARS levels, while their levels of NO2
−,H 2O2, SOD and CAT activities were lower than controls’. vWfAg
showed high speciﬁcity and sensitivity as a test to reveal healthy or diseased subjects. Multivariant logistic regression marked
only vWfAg and TBARS as parameters that were under independent eﬀect of ACS type. The results of our study support the
implementation of vWf in clinical rutine and into therapeutic targets, and suggest that ACS patients are in need of antioxidant
supplementation to improve their impaired antioxidant defence.
1.Introduction
Under physiological conditions, the vascular endothelium
produces many substances that contribute importantly to
hemostasis, ﬁbrinolysis, and regulation of vessel tone and
permeability [1]. One such substance is glycoprotein von
Willebrand factor (vWf), which is almost exclusively pro-
duced by the endothelium, and thus is a marker of endo-
thelial activation or dysfunction [2–4]. vWf mediates platelet
adhesion to the vascular wall, platelet aggregation and serves
as a plasma carrier for factor VIII, stabilizing it in the cir-
culation [5]. Since almost all acute coronary syndromes
(ACSs) result from thrombus formation in pre-existing
atherosclerosis [1], and given the key role of vWf in arterial
thrombus formation, this biomarker attracted considerable
interest as a predictor of cardiovascular disease (CVD) [1, 5].
Previously published studies suggest that there is a weak
association between vWf plasma levels and risk of coronary
heart disease (CHD) in general population, but its predictive
value signiﬁcantly rises in patients with preexisting vascular
disease, diabetics, and the elderly [6–9]. It was noticed that
vWf rises during the course of ACSs [4, 10, 11], and it is
thought that vWf is not only a marker, but also a mediator in
thepathogenesisofmyocardialinfarction(MI)[1].Although
a number of studies pointed out the prognostic value of vWf
[12–14], there is still a long way to go before plasma vWf
levels can be used as a predictor of cardiovascular disease in
clinical practice [5].
von Willebrand factor can be produced and released by
endothelial cells by a variety of stimuli in vitro and in vivo2 Oxidative Medicine and Cellular Longevity
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Figure 1: Values of von Willebrand factor activity (%) in group
of ACSs patient and in group of control subjects (mean + SD).
Compared with control subjects, ACSs patients had statistically
higher levels of vWfAct (175.27 ± 86.52 (166.0) % compared with
118.35 ±33.11 (122.0) %; Mann-Whitney U test; ∗∗P<0.01).
Table 1: Demographic characteristics of investigated groups.
Parameters ACSs patients Controls
Number of patients (n) 115 40
Sex (male/female) 74/41 26/14
Age (X± SD years) 67.0 ±8.06 5 .0 ± 3.0
[5, 15, 16]. A number of substances regulate endothelial
release of vWf. Among other secretion agonists and antag-
onists, like numerous mediators of inﬂammation and/or
thrombosis, reactive oxygen species (ROS) play an impor-
tant role. For example, superoxide anion radical (O2
−)i s
considered to be activator of endothelial exocytosis [17],
while hydrogen peroxide (H2O2) has been shown to inhibit
thrombin-induced vWf secretion in a dose-dependent man-
ner [18]. On the other hand, H2O2 induced a weak secretory
response [19]. Thus, the eﬀects of H2O2 are still to be
investigated. Nitric oxide (NO) is another reactive substance
that exhibits inhibitory eﬀects on vWf secretion, but its
eﬀects are also yet to be elucidated, since the majority of
research was performed on cultured endothelial cells, which
may not be the ideal tool to study the eﬀects of nitric oxide
(NO) [5].
Emerging data suggest that acute presentations of coro-
nary artery disease may involve a complex interplay between
the vessel wall, inﬂammatory cells, and the coagulation
cascade. Considering the role of vWf in hemostasis and the
role of oxidative stress in the development of endothelial
dysfunction and atherosclerotic disease [20–23], the aim of
our study was to investigate the relationship between von
Willebrand factor and parameters of oxidative stress on the
one side and diﬀerent types of acute coronary syndromes on
the other.
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Figure 2: Values of von Willebrand factor antigen (%) in group
of ACSs patient and in group of control subjects (mean + SD).
Compared with control subjects, ACSs patients had statistically
higher levels of vWfAg (284.82 ± 126.66 (261.0) % compared with
104.57 ±25.52 (108.0) %; t-test; ∗∗P<0.01).
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Figure 3:Valuesofnitricoxide(nitrites)levels(nmol/mL)ingroup
of ACSs patient and in group of control subjects (mean + SD).
Compared with control subjects, ACSs patients had statistically
l o w e rl ev e l so fN O 2
− (12.88±8.40 (10.52)nmol/mL compared with
15.98 ±6.05 (17.20)nmol/mL; Mann-Whitney U test; ∗P<0.05).
2. Results
Demographic data of investigated groups are shown in
Table 1.
The results of comparison of investigated biochemical
parameters in patients and controls are shown in Figures 1,
2, 3, 4, 5, 6, 7, 8,a n d9.
Results of uni- and multivariant logistic regression re-
lated to the eﬀects of ACSs existence to changes in examined
biochemical parameters are shown in Table 2. Results of uni-
variant logistic regression marked vWfAg, vWfAct, NO2
−,Oxidative Medicine and Cellular Longevity 3
Table 2: Results of uni- and multivariant logistic regression related to the eﬀects of ACSs existence to changes in examined biochemical
parameters (expB—relative risk; CI—conﬁdence interval; ∗P<0.005; ∗∗P<0.001).
Parameter Univariant logistic regression Multivariant logistic regression
expB (95% CI) Sig. expB (95% CI) Sig.
vWfAct 0.988 (0.981–0.994) P = 0.000
∗∗ 1.033 (0.984–1.084) P = 0.193
vWfAg 0.962 (0.947–0.976) P = 0.000
∗∗ 0.912 (0.810–1.027) P = 0.130
NO2
− 1.062 (1.012–1,114) P = 0.014
∗∗ 1.010 (1.002–1.114) P = 0.914
O2
− 1.005 (0.983–1.028) P = 0.643 — —
H2O2 1.254 (1.124–1.400) P = 0.000
∗∗ 1.054 (1,024–1.300) P = 0.988
TBARS 0.399 (0.251–0.635) P = 0.000
∗∗ 0.999 (0.990–1.100) P = 0.999
SOD 1.007 (1.004–1.011) P = 0.000
∗∗ 1.017 (1.004–1.031) P = 0.899
CAT 1.046 (0.980–1.117) P = 0.174 — —
Table 3: Frequencies of elevated levels of vWfAct and vWfAg in ACSs patients and controls.
Group Sig.
ACSs Controls
vWfAg Elevated levels 99 (86.1%) 0 (0.0%) P = 0.000
∗∗
Normal levels 16 (13.9%) 40 (100.0%)
vWfAct Elevated levels 62 (53.9%) 1 (2.5%) P = 0.000
∗∗
Normal levels 53 (46.1%) 39 (97.5%)
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Figure 4: Values of superoxide anion radical levels (nmol/mL) in
group of ACSs patient and in group of control subjects (mean +
SD). ACSs patients and controls did not diﬀer in levels of O2
− (9.34
+ 7.83 (7.58)nmol/mL compared with 10.63 + 22.90 (5.27); Mann
Whitney U test; P>0.05).
H2O2, TBARS, SOD, and CAT as signiﬁcant. Univariant
logistic regression shows the existence of diﬀerences in
investigated parameters in existance of all other factors,
while multivariant logistic regression marks parameters that
are changed under independent eﬀect of ACSs existance.
Multivariant logistic regression did not mark any parameter
as signiﬁcant.
Frequency of elevated levels of vWfAct (above 163, range
of referent values 48.8%–163%) and vWfAg (above 158,
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Figure 5:Valuesofhydrogen peroxide(nmol/mL)ingroupofACSs
patient and in group of control subjects (mean + SD). Compared
with control subjects, ACSs patients had statistically lower levels
of H2O2 (2.75 ± 2.56 (2.12)nmol/mL compared with 8.11 ± 7.52
(5.21); Mann Whitney U test; ∗∗P<0.01).
range of reerent values: 61.3%–158%) in ACSs patients and
controls are shown in Table 3. χ2 test showed that groups of
ACSspatientsandcontrolsdiﬀeredsigniﬁcantlyinfrequency
of elevated levels of both vWfAct and vWfAg (P = 0.000 for
both).
Based on the data presented in Table 3, sensitivity and
speciﬁcity of the test (measuring vWfAct and vWfAg levels)
werecalculated.Sensitivity, asanindicator ofthe test’s ability
torevealpatientswithdisease(ACSs)was53.91%forvWfAct
and 86.0% for vWfAg, while speciﬁcity, as an indicator of4 Oxidative Medicine and Cellular Longevity
Table 4: Levels of investigated biochemical parameters in diﬀerent subgroups of subjects.
X± SD (median) Sig.
vWfAct (%)
STEMI (n = 65) 185.36 ±95.25 (170.00)
Kruskal-Wallis test: P = 0.000
∗∗
Mann-Whitney U test:
NSTEMI (n = 36) 167.92 ±75.56 (168.50)
STEMI versus NSTEMI P = 0.173
STEMI versus UA P = 0.072
UA (n = 14) 130.48 ±50.34 (121.00)
STEMI versus Control P = 0.000
∗∗
NSTEMI versus UA P = 0.214
Control (n = 40) 118.35 ±33.11 (122.00)
NSTEMI versus Control P = 0.001
∗∗
UA versus Control P = 0.819
vWfAg (%)
STEMI 317.21 ±139.50 (302.00)
ONE way ANOVA: P = 0.000
∗∗
Bonferroni:
NSTEMI 256.40 ±95.23 (229.25)
STEMI versus NSTEMI P = 0.012
∗
STEMI versus UA P = 0.000
∗∗
UA 169.27 ±52.47 (181.50)
STEMI versus Control P = 0.000
∗∗
NSTEMI versus UA P = 0.021
∗
Control 104.57 ±25.52 (108.00)
NSTEMI versus Control P = 0.000
∗∗
UA versus Control P = 0.991
O2
− (nmol/mL)
STEMI 8.90 ±6.91 (7.25)
Kruskal-Wallis test: P = 0.284 NSTEMI 9.68 ±9.45 (7.58)
UA 10.38 ±0.57 (10.54)
Control 10.63 ±22.90 (5.27)
H2O2 (nmol/mL)
STEMI 2.70 ±1.66 (2.14)
Kruskal-Wallis test: P = 0.000
∗∗
Mann-Whitney U test:
NSTEMI 2.41 ±2.04 (1.98)
STEMI versus NSTEMI P = 0.181
STEMI versus UA P = 0.235
UA 5.06 ±7.37 (1.66)
STEMI versus Control P = 0.000
∗∗
NSTEMI versus UA P = 0.872
Control 8.11 ±7.52 (5.21)
NSTEMI versus Control P = 0.000
∗∗
UA versus Control P = 0.000
∗∗
NO2
− (nmol/mL)
STEMI 13.16 ±7.57 (12.65)
ONE way ANOVA: P = 0.081 NSTEMI 13.12 ±9.62 (9.69)
UA 9.54 ±6.95 (7.22)
Control 15.98 ±6.05 (17.20)
TBARS (μmol/mL)
STEMI 3.42 ±2.61 (2.69)
Kruskal-Wallis test: P = 0.000
∗∗
Mann-Whitney U test:
NSTEMI 2.96 ±2.47 (2.21)
STEMI versus NSTEMI P = 0.999
STEMI versus UA P = 0.999
UA 2.10 ±0.56 (2.30)
STEMI versus Control P = 0.000
∗∗
NSTEMI versus UA P = 0.999
Control 1.34 ±0.47 (1.19)
NSTEMI versus Control P = 0.000
∗∗
UA versus Control P = 0.000
∗∗
SOD (U/g Hb ×103)
STEMI 185.04 ±154.82 (124.54)
Kruskal-Wallis test: P = 0.000
∗∗
Mann-Whitney U test:Oxidative Medicine and Cellular Longevity 5
Table 4: Continued.
X± SD (median) Sig.
NSTEMI 140.03 ±129.84 (87.91) STEMI versus NSTEMI P = 0.069
STEMI versus UA P = 0.032
∗
UA 67.20 ±20.95 (66.34) STEMI versus Control P = 0.000
∗∗
NSTEMI versus UA P = 0.615
Control 3078.21 ±2664.35 (2433.71) NSTEMI versus Control P = 0.000
∗∗
UA versus Control P = 0.000
∗∗
CAT (U/g Hb ×103)
STEMI 5.94 ±5.94 (3.25)
Kruskal-Wallis test: P = 0.159 NSTEMI 5.30 ±4.14 (4.37)
UA 4.38 ±2.65 (4.12)
Control 7.80 ±5.10 (6.87)
Table 5: Results of uni- and multivariant logistic regression related to the eﬀects of diﬀerent type ACSs to changes in examined biochemical
parameters (B—unstandardized regression coeﬃcient; CI—conﬁdence interval; ∗P<0.005; ∗∗P<0.001).
Parameter Univariate logistic regression Multivariate logistic regression
B (95% CI) Sig. B (95% CI) Sig.
vWfAct −0.006 (−0.008–(−0.003)) P = 0.000
∗∗ 0.000 (−0.004–0.003) P = 0.948
vWfAg −0.006 (−0.007–(−0.005)) P = 0.000
∗∗ −0.004 (−0.006–(−0.001)) P = 0.007
∗∗
NO 0.027 (0.001–0.053) P = 0.038
∗ −0.002 (−0.026–0.023) P = 0.897
O2 0.003 (−0.010–0.016) P = 0.648 — —
H2O2 0.099 (0.064–0.133) P = 0.000
∗∗ 0.072 (0.013–0.131) P = 0.018
TBARS −0.161 (−0.220–(−0.102)) P = 0.000
∗∗ −0.100 (−0.183–(−0.017)) P = 0.019
∗
SOD 0.000 (0.000–0.000) P = 0.000
∗∗ 0.001 (0.000–0.001) P = 0.262
CAT 0.015 (−0.024–0.053) P = 0.450 — —
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Figure 6: Values of index of lipid peroxidation (TBARS) levels
(μmol/mL) in group of ACSs patient and in group of control
sub-jects (mean + SD). Compared with control subjects, ACSs
patients had statistically higher TBARS compared with control
subjects(3.12±2.45(2.48)U/gHb ×103 comparedwith1.34±0.47
(1.19)U/g Hb × 103; t-test; ∗∗P<0.01).
test’s ability to revel healthy subjects, was 97.5% for vWfAct
and 100.00% for vWfAg. Receiver operating characteristic
(ROC) curve (Figure 9) shows discriminative ability of the
test.
Table 4 shows levels of investigated parameters in groups
of patients with diﬀerent type of ACSs. Results of uni-
and multivariant logistic regression related to the eﬀects of
diﬀ-erent type of ACSs existence to changes in examined
biochemical parameters are shown in Table 5.U n i v a r i a n t
logistic regression marked vWfAg, vWfAct, NO2
−,H 2O2,
TBARS, and SOD as signiﬁcant, while multivariant analysis
showed that only vWfAg and TBARS were under indepen-
dent eﬀect of ACSs type.
Table 6 shows data about investigated biochemical para-
meters in ACSs patients who survived and who deceased.
There was no signiﬁcant diﬀerence in any investigated bio-
chemical parameter between these groups.
Results of univariant logistic regression regarding eﬀects
of levels of biochemical parameters on outcome (survival or
lethal event) of ACSs patients showed that no biochemical
parameterwasrevealedassigniﬁcant,somultivariantlogistic
regression was not performed (Table 7).
3. Discussion
Biomarkers play a pivotal role in the diagnosis and treatment
of patients with cardiovascular disease [24]. Advances in
our understanding of the pathophysiology of ACSs have led
to the marked increase in development of biomarkers for
diagnosis, risk stratiﬁcation, therapeutic decision making,
and assessment of clinical outcomes [25–27]. A lot of
new markers measuring various components of the acute6 Oxidative Medicine and Cellular Longevity
Table 6: Levels of investigated biochemical parameters in ACSs patients who survived and who deceased.
Subjects X± SD (median) Sig.
vWfAct (%)
Survivors (n = 111) 172.00 ±83.94 (168.00) Mann-Whitney U test, P = 0.708
Deceased (n = 4) 189.80 ±105.94 (175.00)
vWfAg (%)
Survivors 274.86 ±120.70 (241.00) Mann-Whitney U test, P = 0.119
Deceased 395.30 ±182.16 (416.00)
NO2
− (nmol/mL)
Survivors 12.68 ±7.86 (12.32) t-test, P = 0.998
Deceased 12.67 ±10.28 (8.18)
O2
− (nmol/mL)
Survivors 9.15 ±10.68 (6.59) Mann-Whitney U test, P = 0.150
Deceased 15.42 ±28.24 (3.62)
H2O2 (nmol/mL)
Survivors 2.99 ±3.53 (2.20) Mann-Whitney U test, P = 0.918
Deceased 2.16 ±0.56 (2.05)
TBARS (μmol/mL)
Survivors 4.26 ±3.39 (2.95) Mann-Whitney U test, P = 0.394
Deceased 5.24 ±3.24 (5.06)
SOD (U/g Hb × 103)
Survivors 157.55 ±125.22 (107.45) Mann-Whitney U test, P = 0.836
Deceased 175.82 ±198,86 (118.03)
CAT (U/g Hb × 103)
Survivors 6.16 ±5.22 (4.00) Mann-Whitney U test, P = 0.073
Deceased 11.30 ±7.36 (10.00)
Table 7: Univariant logistic regression regarding eﬀects of bio-
chemical parameters on outcome of ACSs patients (expB—relative
risk; CI—conﬁdence interval).
Parameter Univariant logistic regression
expB (95% CI) Sig.
vWfAct 1.002 (0.992–1.013) P = 0.647
vWfAg 1.006 (1.000–1.013) P = 0.052
NO2
− 1.000 (0.892–1.121) P = 0.998
O2 1.026 (0.979–1.075) P = 0.291
H2O2 0.846 (0.447–1.599) P = 0.606
TBARS 1.083 (0.843–1.391) P = 0.531
SOD 1.001 (1.995–1.008) P = 0.757
CAT 1.120 (0.995–1.262) P = 0.061
atherothrombotic event have been described, and novel
biomarkersofendothelialactivation,inﬂammation,coagula-
tion, and platelet activation are intensively investigated [28–
31]. Among other perspective prognostic biomarkers that
have not been incorporated into routine clinical use yet, von
Willebrand factor rises considerable attention.
Many diﬀerent vWf-dependent laboratory assays have
been developed to correctly diagnose and classify von Wille-
branddisease[32].However,wheninvestigatingvWfasarisk
factor for cardiovascular disease, assays for plasma vWf anti-
gen and plasma vWf activity are used in most cases [1]. ACSs
patients in our study had signiﬁcantly elevated levels of both
vWfAct and vWfAg compared with healthy control subjects.
Levels of vWfAct did not diﬀer signiﬁcantly among patients
with diﬀerent type of ACSs; vWfAct was elevated only in
STEMI (ST elevation MI) and NSTEMI (non-ST elevation
MI) ACSs patients, while patients with unstable angina had
vWfAct levels similar to control subjects. Regarding vWfAg,
there were signiﬁcant diﬀerences in its level among patients
with diﬀerent types of ACSs as well as between controls and
STEMI and NSTEMI patients. Only vWfAg levels of patients
with UA did not diﬀer from controls. The results of our
study are in consent with previously reported data. Spiel et
al. [1] and Paulinska et al. [16] reported that the published
vWf data [10, 11, 33–37] shows that patients with acute
myocardial infarction (AMI) have markedly increased vWf
values compared with unstable angina (UA) and coronary
artery disease (CAD) patients as well as compared with
healthy control subjects. That vWf is biochemical parameter
that distinguishes well between the healthy and people with
ACSs our study proved not only by assessing diﬀerences in
its levels between ACSs patients and controls, but also by
com-paring the frequency of the existance of elevated vWf
levels in these two groups as well as by counting its speciﬁcity
and sensitivity. Sensitivity of vWfAg, as an indicator of its
ability to reveal patients with disease, was 86%, while its
speciﬁcity, as an indicator of its ability to reveal healthy
subjects, was 100%. Sensitivity of vWfAct was signiﬁcantlyOxidative Medicine and Cellular Longevity 7
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Figure 7: Values of superoxide dismutase activity (U/g Hb × 103)
in group of ACSs patient and in group of control subjects (mean +
SD).Comparedwithcontrolsubjects,ACSspatientshadstatistically
lowerSODactivity(156.83±140.94(89.54)U/gHb×103 compared
with 3078.21 ±2664.35 (2433.71)U/g Hb × 103; Mann-Whitney U
test; ∗∗P<0.01).
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Figure 8: Values of catalase activity (U/g Hb × 103)i ng r o u p
of ACSs patient and in group of control subjects (mean + SD).
Compared with control subjects, ACSs patients had statistically
lower CAT activity (5.55±4.99 (4.00)U/g Hb × 103 compared with
7.80±5.10 (6.87)U/g Hb × 103; Mann-Whitney U test; ∗P<0.05).
lower, but its speciﬁcity was also very high (97.5%). As it
can also be seen from Figure 9 that shows ROC curves for
vWfAct and vWfAg, the strength of vWfAg as an indicator of
ACSs existance is very high. Results of logistic regression also
highlighted this parameter assigniﬁcant—univariant logistic
regression showed that type of ACSs aﬀects both vWfAct
and vWfAg levels, but multivariant regression marked only
vWfAg as the one whose change is under independent eﬀect
of ACSs type not due to existance of other cofactors.
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Figure 9: Based on the data about sensitivity and speciﬁcity of
the test (measuring vWfAct and vWfAg levels), receiver operating
characteristic (ROC) curve as an indicator of the discriminating
ability of the vWfAct and vWfAct test was obtained. ROC curve
shows that the strength of vWfAg as an indicator of ACSs existence
is very high.
The results of previous studies regarding prognostic
value of vWf for cardiovascular events are equivocal. Many
studies found increased relative risk in subjects with the
highest levels of vWf [6, 38, 39], but in the majority
of studies, the association between vWf and CHD risk
disappeared after adjustment for conventional risk factors
[8, 9]. However, in contrast to results of studies performed in
the general population, in patients with preexisting vascular
disease, vWf revealed as signiﬁcantly predictive parameter
for adverse cardiac events, including death [13, 14, 40–42].
Our study was not prospective, but since 4 patients died few
days after admission, we compared their admission levels of
investigated biochemical parameters with levels of patients
that survived. No statistical diﬀerence was found, neither in
vWfAct and vWfAg levels, nor in levels of redox parameters.
The second part of our investigation related to the
assessment of subjects’ redox state. Oxidative stress has been
suggested to play an important role in the development
of more than two hundred acute and chronic human di-
seases as well as in aging [21–23, 43–46]. The results of
our study showed that ACSs patients had signiﬁcantly less
eﬃcient antioxidative defence system compared with con-
trols (signiﬁcantly lower levels of SOD and CAT activity)
which resulted in signiﬁcantly increased levels of lipid pero-
xidation. Furthermore, ACSs patients had signiﬁcantly lower
levels of nitric oxide (nitrites), which is an indicator of
endothelial dysfunction. Suprisingly, H2O2 levels of ACSs
patients were signiﬁcantly lower than controls’. The fact that8 Oxidative Medicine and Cellular Longevity
ACSspatientshadlowerNOandH2O2 levelsmaybebrought
intoconnectionwithvWflevels,sincereactiveoxygenspecies
and NO are involved in the regulation of vWf release. It
was previously suggested that the blockade of nitric oxide
enhances the stimulated release of vWf in humans [47, 48],
that is, NO exerts inhibitory eﬀects on vWf release [5].
So, is thought for H2O2 [5]. ACSs patients were deﬁcient
in NO and H2O2 compared with controls, so NO and
H2O2 inhibition of vWf release was probably lower. When
comparing oxidative status of patients with diﬀerent ACSs
types, only SOD diﬀered between STEMI and UA patients
(UA patients had lower SOD activity). On the other hand,
whenever the diﬀerence among 4 groups (3 ACSs groups and
control group; Table 4) was found, it related to diﬀerences
between every group of ACSs patients and controls. These
results suggest that ACSs patients are under higher oxidative
stress compared with control subjects, no matter which type
of ACSs they have. However, although ACSs patients diﬀered
from controls in a few oxidative stress parameters, only
TBARSwasfoundtobeundertheindependenteﬀectofACSs
type.
The results of our study point out to von Willebrand
factor antigen as strong indicator of existance of any kind of
ACSs. This supports the implementation of vWf in clinical
routine and into therapeutic targets. Results related to the
investigation of oxidative stress in ACSs patients suggest
that antioxidant supplementation is needed to improve the
antioxidant defence, since enzymatic antioxidant defense is
compromised and lipid peroxidation consequently increased
in those patients.
4. Patientsand Methods
4.1. Subjects. The research was carried out within a group
of 115 patients who were consecutively admitted to the
Intensive Care Unit of University Hospital Center “Kraguje-
vac”, Serbia. All patients met the criteria for ACSs diagnosis
(the presence of two out of these three criteria is enough
to diagnose ACSs): (1) chest pain, (2) electrocardiographic
changes (ST elevation or depression ≥1mm, or T wave
inversion), and (3) serum cardiac markers changes (creatine
kinase (CK), creatine kinase MB (CK-MB), and troponin
T( T n T ) )[ 49]. The diagnosis of STEMI was deﬁned as the
concurrence of prolonged chest pain or discomfort with
persistent ST-segment elevation of greater than 1mm in
2 or more contiguous leads or with presumed new left
bundle-branch block with cardiac enzymes (total creatine
kinase and creatine kinase MB fraction) above twice the
upper normal limit [50]. The diagnosis of NSTEMI included
the presence of typical angina at rest associated with acute
and transient ST-segment or T-wave changes with cardiac
enzymesabovetwicetheuppernormallimit,raisedtroponin
I levels to at least “high risk” values (>0.6ng/mL), or both
[50]. Patients with clinical or electrocardiographic (ECG)
features of non-STEMI but with normal cardiac enzymes
plus normal troponin levels were classiﬁed as UA [50].
The study was approved by Ethical committee of Univer-
sity Hospital Center “Kragujevac”, Serbia.
4.2. Protocol. After admission to hospital patients were taken
a blood sample from which von Willebrand factor activity
(vWfAct), von Willebrand antigen (vWfAg), levels of nitric
oxide (NO), superoxide anion radical (O2
−), hydrogen
peroxide (H2O2), index of lipid peroxidation (TBARS),
superoxide dismutase activity (SOD), and catalase activity
(CAT) were determined.
4.3. Biochemical Assays. Blood samples were taken from the
antecubitalveinsintoVacutainertesttubecontainingsodium
citrate anticoagulant. Blood was centrifuged to separate pla-
sma and red blood cells (RBCs).
4.4. von Willebrand Factor Activity and von Willebrand Fac-
tor Antigen Determination. Determination of vWfAct and
vWfAg was performed using commercial assay kit (HemosIL
0020004700 and 0020002300) on ACL Elite Pro appara-
tus manufactured by Instrumentation Laboratory, Bedford,
Mass, USA. vWfAct and vWfAg results are reported in % of
normality.
4.5. Nitric Oxide Determination. Nitric oxide (NO) decom-
poses rapidly to form stable metabolite nitrite/nitrate prod-
ucts. Nitrite (NO2
−) was determined as an index of nitric
oxide production with Griess reagent [51]. 0.1mL 3N PCA
(Perchloride acid), 0.4mL 20mM EDTA (ethylenediamine-
tetraacetic acid), and 0.2mL plasma were put on ice for
15min then centrifuged 15min at 6000rpm. After pouring
oﬀ the supernatant, 220μLK 2CO3 was added. Nitrites were
measured at 550nm. Distilled water was used as a blank
probe.
4.6. Superoxide Anion Radical Determination. The level of
superoxide anion radical (O2
−) was measured using NBT
(nitro blue tetrazolium) reaction in TRIS-buﬀer combined
with plasma samples and read at 530nm [52].
4.7. Hydrogen Peroxide Determination. The protocol for
measurement of hydrogen peroxide (H2O2)i sb a s e do n
oxidation of phenol red in the presence of horseradish
peroxidase [53]. Two hundred μL sample with 800μLP R S
(phenol red solution) and 10μL POD (horse radish per-
oxidase) were combined (1:20). The level of H2O2 was
measured at 610nm.
4.8. Index of Lipid Peroxidation (Thiobarbituric Acid Reactive
Substances, TBARS). The degree of lipid peroxidation in
plasmawasestimatedbymeasuringofthiobarbituricacidre-
active substances (TBARS) using 1% TBA (Thiobarbituric
Acid) in 0.05 NaOH, incubated with plasma at 100◦Cf o r
15min and read at 530nm. Distilled water was used as a
blank probe. TBA extract was obtained by combining 0.8mL
plasma and 0.4mL TCA (trichloro acetic acid), then samples
were put on ice for 10 minutes and centrifuged for 15min at
6000rpm. This method was described previously [54].
4.9. Determination of Antioxidant Enzymes. Isolated RBCs
were washed three times with 3 volumes of ice-coldOxidative Medicine and Cellular Longevity 9
0.9mmol/L NaCl, and hemolysates containing about
50gHb/L (prepared according to McCord and Fridovich
[55]) were used for the determination of catalase (CAT)
activity. CAT activity was determined according to Beutler
[56]. Lysates were diluted with distilled water (1:7v/v)
and treated with chloroform-ethanol (0.6:1v/v) to remove
haemoglobin [57]. Then, 50μL catalase buﬀer, 100μL
sample, and 1mL 10 mM H2O2 were added to the samples.
Detection was performed at 360nm. Distilled water was
used as a blank probe. Superoxide dismutase (SOD) activity
was determined by the epinephrine method of Misra and
Fridovich [58]. A hundred μL lysate and 1mL carbonate
buﬀer were mixed, and then, 100μL of epinephrine was
added. Detection was performed at 470nm.
4.10. Statistics. The statistical analysis was performed with
SPSS 10.0 for Windows. Results are expressed as the means ±
standard deviation (median). Data on ﬁgures is presented as
mean + standard deviation. After checking data distribution,
the appropriate parametric or nonparametric test was used.
The diﬀerences between two groups were assessed using t-
test or Mann-Whitney test, while the diﬀerences between
morethanthreegroupswereassessedusingone-wayANOVA
or Kruskal-Wallis test. For ANOVA posthoc analysis, Bon-
ferroni test was used. To deﬁne the parameters that mostly
change in ACSs, univariant logistic regression was used.
Parameters that were marked as signiﬁcant in univariant
logistic regression entered multivariant logistic regression.
Multivariantlogistic regressionmarkedparametersthatwere
under independent eﬀect of ACSs. χ2 test was used to assess
the diﬀerence in frequency of elevated levels of vWfAct and
vWfAg. Based on the data about this frequency, sensitivity
and speciﬁcity of the test (vWfAct and vWfAg test) were
calculated. Based on the data about sensitivity and speciﬁcity
ofthetest,thereceiveroperatingcharacteristics(ROC)curve
was determined.
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